Canadian application, no grantCanada
Method of decreasing fasting sugars and weight gains in diabetic patients
CA 2390757 A1 · Owner: Pfizer Products Inc. · Inventors: Landschulz, William Harras
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Inhaled insulin, relative to subcutaneously and/or transdermally administered insulin, can be used to prevent the rate of weight gain and to lower the levels of, fasting glucose in diabetic patients.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 17, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 17, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 17, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJune 17, 2002
GrantedNo grant recorded
Term endedJune 17, 2022
Patent numberCA 2390757 A1
Classification (IPC)A61K38/28 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.